IDYA
Price
$31.81
Change
-$0.14 (-0.44%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
2.8B
138 days until earnings call
Intraday BUY SELL Signals
OCUL
Price
$11.18
Change
-$0.31 (-2.70%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
2.45B
116 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IDYA vs OCUL

Header iconIDYA vs OCUL Comparison
Open Charts IDYA vs OCULBanner chart's image
IDEAYA Biosciences
Price$31.81
Change-$0.14 (-0.44%)
Volume$10.63K
Capitalization2.8B
Ocular Therapeutix
Price$11.18
Change-$0.31 (-2.70%)
Volume$47.12K
Capitalization2.45B
IDYA vs OCUL Comparison Chart in %
IDYA
Daily Signal:
Gain/Loss:
OCUL
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
IDYA vs. OCUL commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a StrongBuy and OCUL is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (IDYA: $31.95 vs. OCUL: $11.49)
Brand notoriety: IDYA and OCUL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 69% vs. OCUL: 65%
Market capitalization -- IDYA: $2.8B vs. OCUL: $2.45B
IDYA [@Biotechnology] is valued at $2.8B. OCUL’s [@Biotechnology] market capitalization is $2.45B. The market cap for tickers in the [@Biotechnology] industry ranges from $110.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 1 FA rating(s) are green whileOCUL’s FA Score has 0 green FA rating(s).

  • IDYA’s FA Score: 1 green, 4 red.
  • OCUL’s FA Score: 0 green, 5 red.
According to our system of comparison, IDYA is a better buy in the long-term than OCUL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 3 TA indicator(s) are bullish while OCUL’s TA Score has 5 bullish TA indicator(s).

  • IDYA’s TA Score: 3 bullish, 5 bearish.
  • OCUL’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, OCUL is a better buy in the short-term than IDYA.

Price Growth

IDYA (@Biotechnology) experienced а +7.72% price change this week, while OCUL (@Biotechnology) price change was +6.29% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Reported Earning Dates

IDYA is expected to report earnings on Mar 31, 2026.

OCUL is expected to report earnings on Mar 09, 2026.

Industries' Descriptions

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($2.8B) has a higher market cap than OCUL($2.45B). OCUL YTD gains are higher at: 34.543 vs. IDYA (24.319). OCUL has higher annual earnings (EBITDA): -200.5M vs. IDYA (-380.2M). IDYA has more cash in the bank: 670M vs. OCUL (391M). IDYA has less debt than OCUL: IDYA (26.6M) vs OCUL (76.9M). OCUL has higher revenues than IDYA: OCUL (56.7M) vs IDYA (7M).
IDYAOCULIDYA / OCUL
Capitalization2.8B2.45B114%
EBITDA-380.2M-200.5M190%
Gain YTD24.31934.54370%
P/E RatioN/AN/A-
Revenue7M56.7M12%
Total Cash670M391M171%
Total Debt26.6M76.9M35%
FUNDAMENTALS RATINGS
IDYA vs OCUL: Fundamental Ratings
IDYA
OCUL
OUTLOOK RATING
1..100
7969
VALUATION
overvalued / fair valued / undervalued
1..100
26
Undervalued
51
Fair valued
PROFIT vs RISK RATING
1..100
6394
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
3850
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5065

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (26) in the null industry is in the same range as OCUL (51) in the Pharmaceuticals Other industry. This means that IDYA’s stock grew similarly to OCUL’s over the last 12 months.

IDYA's Profit vs Risk Rating (63) in the null industry is in the same range as OCUL (94) in the Pharmaceuticals Other industry. This means that IDYA’s stock grew similarly to OCUL’s over the last 12 months.

IDYA's SMR Rating (96) in the null industry is in the same range as OCUL (97) in the Pharmaceuticals Other industry. This means that IDYA’s stock grew similarly to OCUL’s over the last 12 months.

IDYA's Price Growth Rating (38) in the null industry is in the same range as OCUL (50) in the Pharmaceuticals Other industry. This means that IDYA’s stock grew similarly to OCUL’s over the last 12 months.

IDYA's P/E Growth Rating (100) in the null industry is in the same range as OCUL (100) in the Pharmaceuticals Other industry. This means that IDYA’s stock grew similarly to OCUL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYAOCUL
RSI
ODDS (%)
Bearish Trend 2 days ago
67%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bearish Trend 2 days ago
69%
Bullish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
Bearish Trend 9 days ago
77%
Bearish Trend 8 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signal:
Gain/Loss:
OCUL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MGRVX50.580.27
+0.54%
MFS International Growth R4
DHPIX18.470.06
+0.33%
Diamond Hill Mid Cap I
ALMAX13.760.04
+0.29%
Alger Weatherbie Specialized Growth A
NMFIX14.180.04
+0.28%
Northern Multi-Mgr Glbl Listed Infra
CMSCX34.74-0.04
-0.12%
Columbia Small Cap Growth Inst

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with NUVL. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
-0.19%
NUVL - IDYA
59%
Loosely correlated
+0.91%
NRIX - IDYA
58%
Loosely correlated
-5.37%
IMNM - IDYA
57%
Loosely correlated
-0.51%
CGON - IDYA
57%
Loosely correlated
+1.47%
XENE - IDYA
57%
Loosely correlated
-0.60%
More

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with IDYA. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
+2.41%
IDYA - OCUL
57%
Loosely correlated
-0.19%
EYPT - OCUL
55%
Loosely correlated
+2.96%
DNLI - OCUL
55%
Loosely correlated
-0.34%
ERAS - OCUL
54%
Loosely correlated
+12.29%
RVMD - OCUL
53%
Loosely correlated
+2.73%
More